HC Wainwright Lowers Day One Biopharmaceuticals (NASDAQ:DAWN) Price Target to $40.00

Day One Biopharmaceuticals (NASDAQ:DAWN) had its price target cut by HC Wainwright from $50.00 to $40.00 in a report released on Tuesday, Benzinga reports. They currently have a buy rating on the stock.

A number of other research firms also recently weighed in on DAWN. JPMorgan Chase & Co. upped their price target on Day One Biopharmaceuticals from $32.00 to $36.00 and gave the stock an overweight rating in a research note on Monday, April 22nd. The Goldman Sachs Group dropped their price target on Day One Biopharmaceuticals from $50.00 to $44.00 and set a buy rating on the stock in a research note on Tuesday, February 27th. Needham & Company LLC upped their price target on Day One Biopharmaceuticals from $30.00 to $33.00 and gave the stock a buy rating in a research note on Wednesday, April 24th. Piper Sandler reaffirmed an overweight rating and set a $40.00 price target on shares of Day One Biopharmaceuticals in a research note on Tuesday, March 26th. Finally, Oppenheimer reaffirmed a market perform rating on shares of Day One Biopharmaceuticals in a research note on Tuesday, February 27th. One research analyst has rated the stock with a hold rating and six have assigned a buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of Moderate Buy and a consensus price target of $37.67.

Day One Biopharmaceuticals Price Performance

Shares of NASDAQ:DAWN opened at $17.08 on Tuesday. The company has a market capitalization of $1.49 billion, a price-to-earnings ratio of -7.18 and a beta of -1.44. The business’s 50-day moving average is $15.47 and its 200-day moving average is $14.12. Day One Biopharmaceuticals has a 1 year low of $9.67 and a 1 year high of $18.07.

Day One Biopharmaceuticals (NASDAQ:DAWN) last announced its quarterly earnings data on Monday, February 26th. The company reported ($0.64) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.57) by ($0.07). Analysts anticipate that Day One Biopharmaceuticals will post -2.67 EPS for the current year.

Insider Transactions at Day One Biopharmaceuticals

In other news, insider Samuel C. Blackman sold 2,258 shares of the stock in a transaction that occurred on Friday, February 16th. The stock was sold at an average price of $15.25, for a total value of $34,434.50. Following the completion of the sale, the insider now directly owns 1,244,662 shares of the company’s stock, valued at $18,981,095.50. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. In other news, General Counsel Adam Dubow sold 3,242 shares of the company’s stock in a transaction that occurred on Friday, February 16th. The stock was sold at an average price of $15.25, for a total value of $49,440.50. Following the completion of the transaction, the general counsel now directly owns 16,585 shares of the company’s stock, valued at $252,921.25. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, insider Samuel C. Blackman sold 2,258 shares of the company’s stock in a transaction that occurred on Friday, February 16th. The shares were sold at an average price of $15.25, for a total value of $34,434.50. Following the completion of the transaction, the insider now directly owns 1,244,662 shares of the company’s stock, valued at $18,981,095.50. The disclosure for this sale can be found here. Insiders sold a total of 195,247 shares of company stock valued at $3,376,817 over the last ninety days. 8.40% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Day One Biopharmaceuticals

Several institutional investors and hedge funds have recently bought and sold shares of the company. Vanguard Group Inc. grew its holdings in Day One Biopharmaceuticals by 8.1% during the third quarter. Vanguard Group Inc. now owns 4,629,754 shares of the company’s stock valued at $56,807,000 after purchasing an additional 346,090 shares during the period. Franklin Resources Inc. grew its holdings in Day One Biopharmaceuticals by 4.2% during the fourth quarter. Franklin Resources Inc. now owns 4,236,795 shares of the company’s stock valued at $61,857,000 after purchasing an additional 169,463 shares during the period. Braidwell LP grew its holdings in Day One Biopharmaceuticals by 13.5% during the fourth quarter. Braidwell LP now owns 4,215,573 shares of the company’s stock valued at $61,547,000 after purchasing an additional 500,000 shares during the period. Goldman Sachs Group Inc. grew its holdings in Day One Biopharmaceuticals by 28.7% during the fourth quarter. Goldman Sachs Group Inc. now owns 2,118,849 shares of the company’s stock valued at $30,935,000 after purchasing an additional 472,654 shares during the period. Finally, Polar Capital Holdings Plc grew its holdings in Day One Biopharmaceuticals by 9.0% during the third quarter. Polar Capital Holdings Plc now owns 1,935,000 shares of the company’s stock valued at $23,742,000 after purchasing an additional 160,385 shares during the period. 87.95% of the stock is owned by institutional investors.

Day One Biopharmaceuticals Company Profile

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.